Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Cost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Axsome Therapeutics (AXSM) EBIAT (2022 - 2026)

Axsome Therapeutics' EBIAT history spans 5 years, with the latest figure at -$64.5 million for Q1 2026.

  • On a quarterly basis, EBIAT fell 8.63% to -$64.5 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$188.3 million, a 32.33% increase, with the full-year FY2025 number at -$183.2 million, up 36.22% from a year prior.
  • EBIAT hit -$64.5 million in Q1 2026 for Axsome Therapeutics, down from -$28.6 million in the prior quarter.
  • Over the last five years, EBIAT for AXSM hit a ceiling of -$11.2 million in Q1 2023 and a floor of -$98.7 million in Q4 2023.
  • Historically, EBIAT has averaged -$56.5 million across 5 years, with a median of -$61.2 million in 2022.
  • Biggest five-year swings in EBIAT: soared 71.69% in 2023 and later plummeted 509.35% in 2024.
  • Tracing AXSM's EBIAT over 5 years: stood at -$61.2 million in 2022, then tumbled by 61.09% to -$98.7 million in 2023, then grew by 24.06% to -$74.9 million in 2024, then soared by 61.88% to -$28.6 million in 2025, then tumbled by 126.0% to -$64.5 million in 2026.
  • Business Quant data shows EBIAT for AXSM at -$64.5 million in Q1 2026, -$28.6 million in Q4 2025, and -$47.2 million in Q3 2025.